How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Sell
19
YBGJ Quote, Financials, Valuation and Earnings
Last price:
$0.0100
Seasonality move
:
100.08%
Day range:
$0.0115 - $0.0115
52-week range:
$0.0079 - $0.1776
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
12.99x
P/B ratio:
--
Volume:
--
Avg. volume:
7.4K
1-year change:
-74.56%
Market cap:
$2M
Revenue:
$3.5K
EPS (TTM):
-$0.01
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
YBGJ
Yubo International Biotech Ltd.
|
-- | -- | -- | -- | -- |
|
HOLX
Hologic, Inc.
|
$1.1B | $1.10 | 2.74% | 26.98% | $77.36 |
|
LNMG
Linike Medical Group Ltd.
|
-- | -- | -- | -- | -- |
|
NUWE
Nuwellis, Inc.
|
$2.3M | -- | -0.52% | -- | $13.00 |
|
QTRX
Quanterix Corp.
|
$38M | -$0.69 | 20.97% | -- | $7.33 |
|
VREX
Varex Imaging Corp.
|
$207.8M | $0.13 | 0.78% | 39.1% | $17.20 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
YBGJ
Yubo International Biotech Ltd.
|
$0.0115 | -- | $2M | -- | $0.00 | 0% | 12.99x |
|
HOLX
Hologic, Inc.
|
$74.93 | $77.36 | $16.7B | 31.09x | $0.00 | 0% | 4.10x |
|
LNMG
Linike Medical Group Ltd.
|
$0.0320 | -- | $111.2K | -- | $0.00 | 0% | 1.78x |
|
NUWE
Nuwellis, Inc.
|
$3.77 | $13.00 | $26.2M | -- | $0.00 | 0% | 1.01x |
|
QTRX
Quanterix Corp.
|
$6.34 | $7.33 | $296.1M | -- | $0.00 | 0% | 1.97x |
|
VREX
Varex Imaging Corp.
|
$13.94 | $17.20 | $581.2M | 17.58x | $0.00 | 0% | 0.72x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
YBGJ
Yubo International Biotech Ltd.
|
-9.09% | -1.691 | 5.91% | 0.05x |
|
HOLX
Hologic, Inc.
|
32.46% | 1.135 | 15.17% | 3.14x |
|
LNMG
Linike Medical Group Ltd.
|
-- | 5.922 | -- | -- |
|
NUWE
Nuwellis, Inc.
|
8.91% | -1.988 | 1.64% | 1.20x |
|
QTRX
Quanterix Corp.
|
11.31% | 1.821 | 15.83% | 2.19x |
|
VREX
Varex Imaging Corp.
|
45.96% | 1.639 | 75.99% | 1.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
YBGJ
Yubo International Biotech Ltd.
|
-$43.6K | -$310.1K | -- | -- | -11737.99% | -$359.1K |
|
HOLX
Hologic, Inc.
|
$584.1M | $240.9M | 7.3% | 11.09% | 22.99% | $194.8M |
|
LNMG
Linike Medical Group Ltd.
|
-- | -- | -- | -- | -- | -- |
|
NUWE
Nuwellis, Inc.
|
$1.4M | -$2.7M | -773.58% | -1004.06% | -121.65% | -$3.2M |
|
QTRX
Quanterix Corp.
|
$17.2M | -$30.2M | -26.87% | -30.04% | -74.94% | -$41.9M |
|
VREX
Varex Imaging Corp.
|
$77.8M | $19.6M | -6.87% | -13.35% | 8.56% | $2.3M |
Yubo International Biotech Ltd. vs. Competitors
-
Which has Higher Returns YBGJ or HOLX?
Hologic, Inc. has a net margin of -11740.4% compared to Yubo International Biotech Ltd.'s net margin of 17.09%. Yubo International Biotech Ltd.'s return on equity of -- beat Hologic, Inc.'s return on equity of 11.09%.
Company Gross Margin Earnings Per Share Invested Capital YBGJYubo International Biotech Ltd.76.29% -$0.00 -$1.5M HOLXHologic, Inc.55.75% $0.79 $7.8B -
What do Analysts Say About YBGJ or HOLX?
Yubo International Biotech Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Hologic, Inc. has an analysts' consensus of $77.36 which suggests that it could grow by 3.25%. Given that Hologic, Inc. has higher upside potential than Yubo International Biotech Ltd., analysts believe Hologic, Inc. is more attractive than Yubo International Biotech Ltd..
Company Buy Ratings Hold Ratings Sell Ratings YBGJYubo International Biotech Ltd.0 0 0 HOLXHologic, Inc.1 16 0 -
Is YBGJ or HOLX More Risky?
Yubo International Biotech Ltd. has a beta of 0.649, which suggesting that the stock is 35.054% less volatile than S&P 500. In comparison Hologic, Inc. has a beta of 0.695, suggesting its less volatile than the S&P 500 by 30.493%.
-
Which is a Better Dividend Stock YBGJ or HOLX?
Yubo International Biotech Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hologic, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Yubo International Biotech Ltd. pays -- of its earnings as a dividend. Hologic, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios YBGJ or HOLX?
Yubo International Biotech Ltd. quarterly revenues are --, which are smaller than Hologic, Inc. quarterly revenues of $1B. Yubo International Biotech Ltd.'s net income of -$310.2K is lower than Hologic, Inc.'s net income of $179.1M. Notably, Yubo International Biotech Ltd.'s price-to-earnings ratio is -- while Hologic, Inc.'s PE ratio is 31.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Yubo International Biotech Ltd. is 12.99x versus 4.10x for Hologic, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income YBGJYubo International Biotech Ltd.12.99x -- -- -$310.2K HOLXHologic, Inc.4.10x 31.09x $1B $179.1M
-
Which has Higher Returns YBGJ or LNMG?
Linike Medical Group Ltd. has a net margin of -11740.4% compared to Yubo International Biotech Ltd.'s net margin of --. Yubo International Biotech Ltd.'s return on equity of -- beat Linike Medical Group Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital YBGJYubo International Biotech Ltd.76.29% -$0.00 -$1.5M LNMGLinike Medical Group Ltd.-- -- -- -
What do Analysts Say About YBGJ or LNMG?
Yubo International Biotech Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Linike Medical Group Ltd. has an analysts' consensus of -- which suggests that it could grow by 107934.47%. Given that Linike Medical Group Ltd. has higher upside potential than Yubo International Biotech Ltd., analysts believe Linike Medical Group Ltd. is more attractive than Yubo International Biotech Ltd..
Company Buy Ratings Hold Ratings Sell Ratings YBGJYubo International Biotech Ltd.0 0 0 LNMGLinike Medical Group Ltd.0 0 0 -
Is YBGJ or LNMG More Risky?
Yubo International Biotech Ltd. has a beta of 0.649, which suggesting that the stock is 35.054% less volatile than S&P 500. In comparison Linike Medical Group Ltd. has a beta of -6.439, suggesting its less volatile than the S&P 500 by 743.861%.
-
Which is a Better Dividend Stock YBGJ or LNMG?
Yubo International Biotech Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Linike Medical Group Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Yubo International Biotech Ltd. pays -- of its earnings as a dividend. Linike Medical Group Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios YBGJ or LNMG?
Yubo International Biotech Ltd. quarterly revenues are --, which are larger than Linike Medical Group Ltd. quarterly revenues of --. Yubo International Biotech Ltd.'s net income of -$310.2K is higher than Linike Medical Group Ltd.'s net income of --. Notably, Yubo International Biotech Ltd.'s price-to-earnings ratio is -- while Linike Medical Group Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Yubo International Biotech Ltd. is 12.99x versus 1.78x for Linike Medical Group Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income YBGJYubo International Biotech Ltd.12.99x -- -- -$310.2K LNMGLinike Medical Group Ltd.1.78x -- -- --
-
Which has Higher Returns YBGJ or NUWE?
Nuwellis, Inc. has a net margin of -11740.4% compared to Yubo International Biotech Ltd.'s net margin of 21.11%. Yubo International Biotech Ltd.'s return on equity of -- beat Nuwellis, Inc.'s return on equity of -1004.06%.
Company Gross Margin Earnings Per Share Invested Capital YBGJYubo International Biotech Ltd.76.29% -$0.00 -$1.5M NUWENuwellis, Inc.65.18% $0.56 $4.3M -
What do Analysts Say About YBGJ or NUWE?
Yubo International Biotech Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Nuwellis, Inc. has an analysts' consensus of $13.00 which suggests that it could grow by 12154.65%. Given that Nuwellis, Inc. has higher upside potential than Yubo International Biotech Ltd., analysts believe Nuwellis, Inc. is more attractive than Yubo International Biotech Ltd..
Company Buy Ratings Hold Ratings Sell Ratings YBGJYubo International Biotech Ltd.0 0 0 NUWENuwellis, Inc.0 1 0 -
Is YBGJ or NUWE More Risky?
Yubo International Biotech Ltd. has a beta of 0.649, which suggesting that the stock is 35.054% less volatile than S&P 500. In comparison Nuwellis, Inc. has a beta of -0.186, suggesting its less volatile than the S&P 500 by 118.573%.
-
Which is a Better Dividend Stock YBGJ or NUWE?
Yubo International Biotech Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nuwellis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Yubo International Biotech Ltd. pays -- of its earnings as a dividend. Nuwellis, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios YBGJ or NUWE?
Yubo International Biotech Ltd. quarterly revenues are --, which are smaller than Nuwellis, Inc. quarterly revenues of $2.2M. Yubo International Biotech Ltd.'s net income of -$310.2K is lower than Nuwellis, Inc.'s net income of $468K. Notably, Yubo International Biotech Ltd.'s price-to-earnings ratio is -- while Nuwellis, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Yubo International Biotech Ltd. is 12.99x versus 1.01x for Nuwellis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income YBGJYubo International Biotech Ltd.12.99x -- -- -$310.2K NUWENuwellis, Inc.1.01x -- $2.2M $468K
-
Which has Higher Returns YBGJ or QTRX?
Quanterix Corp. has a net margin of -11740.4% compared to Yubo International Biotech Ltd.'s net margin of -83.31%. Yubo International Biotech Ltd.'s return on equity of -- beat Quanterix Corp.'s return on equity of -30.04%.
Company Gross Margin Earnings Per Share Invested Capital YBGJYubo International Biotech Ltd.76.29% -$0.00 -$1.5M QTRXQuanterix Corp.42.77% -$0.73 $354.7M -
What do Analysts Say About YBGJ or QTRX?
Yubo International Biotech Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Quanterix Corp. has an analysts' consensus of $7.33 which suggests that it could grow by 15.67%. Given that Quanterix Corp. has higher upside potential than Yubo International Biotech Ltd., analysts believe Quanterix Corp. is more attractive than Yubo International Biotech Ltd..
Company Buy Ratings Hold Ratings Sell Ratings YBGJYubo International Biotech Ltd.0 0 0 QTRXQuanterix Corp.0 3 0 -
Is YBGJ or QTRX More Risky?
Yubo International Biotech Ltd. has a beta of 0.649, which suggesting that the stock is 35.054% less volatile than S&P 500. In comparison Quanterix Corp. has a beta of 1.006, suggesting its more volatile than the S&P 500 by 0.60500000000001%.
-
Which is a Better Dividend Stock YBGJ or QTRX?
Yubo International Biotech Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quanterix Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Yubo International Biotech Ltd. pays -- of its earnings as a dividend. Quanterix Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios YBGJ or QTRX?
Yubo International Biotech Ltd. quarterly revenues are --, which are smaller than Quanterix Corp. quarterly revenues of $40.2M. Yubo International Biotech Ltd.'s net income of -$310.2K is higher than Quanterix Corp.'s net income of -$33.5M. Notably, Yubo International Biotech Ltd.'s price-to-earnings ratio is -- while Quanterix Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Yubo International Biotech Ltd. is 12.99x versus 1.97x for Quanterix Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income YBGJYubo International Biotech Ltd.12.99x -- -- -$310.2K QTRXQuanterix Corp.1.97x -- $40.2M -$33.5M
-
Which has Higher Returns YBGJ or VREX?
Varex Imaging Corp. has a net margin of -11740.4% compared to Yubo International Biotech Ltd.'s net margin of 5.33%. Yubo International Biotech Ltd.'s return on equity of -- beat Varex Imaging Corp.'s return on equity of -13.35%.
Company Gross Margin Earnings Per Share Invested Capital YBGJYubo International Biotech Ltd.76.29% -$0.00 -$1.5M VREXVarex Imaging Corp.33.99% $0.29 $888.5M -
What do Analysts Say About YBGJ or VREX?
Yubo International Biotech Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Varex Imaging Corp. has an analysts' consensus of $17.20 which suggests that it could grow by 23.39%. Given that Varex Imaging Corp. has higher upside potential than Yubo International Biotech Ltd., analysts believe Varex Imaging Corp. is more attractive than Yubo International Biotech Ltd..
Company Buy Ratings Hold Ratings Sell Ratings YBGJYubo International Biotech Ltd.0 0 0 VREXVarex Imaging Corp.3 1 0 -
Is YBGJ or VREX More Risky?
Yubo International Biotech Ltd. has a beta of 0.649, which suggesting that the stock is 35.054% less volatile than S&P 500. In comparison Varex Imaging Corp. has a beta of 0.861, suggesting its less volatile than the S&P 500 by 13.881%.
-
Which is a Better Dividend Stock YBGJ or VREX?
Yubo International Biotech Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Varex Imaging Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Yubo International Biotech Ltd. pays -- of its earnings as a dividend. Varex Imaging Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios YBGJ or VREX?
Yubo International Biotech Ltd. quarterly revenues are --, which are smaller than Varex Imaging Corp. quarterly revenues of $228.9M. Yubo International Biotech Ltd.'s net income of -$310.2K is lower than Varex Imaging Corp.'s net income of $12.2M. Notably, Yubo International Biotech Ltd.'s price-to-earnings ratio is -- while Varex Imaging Corp.'s PE ratio is 17.58x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Yubo International Biotech Ltd. is 12.99x versus 0.72x for Varex Imaging Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income YBGJYubo International Biotech Ltd.12.99x -- -- -$310.2K VREXVarex Imaging Corp.0.72x 17.58x $228.9M $12.2M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Sell
50
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Sell
40
GDXU alert for Jan 31
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 38.85% over the past day.
Sell
34
PFSI alert for Jan 31
PennyMac Financial Services, Inc. [PFSI] is down 33.21% over the past day.
Sell
40
SHNY alert for Jan 31
MicroSectors Gold 3X Leveraged ETN [SHNY] is down 31.56% over the past day.
